Why Are NanoViricides Shares Gaining Today
Why Are NanoViricides Shares Gaining Today
NanoViricides Inc (NYSE:NNVC) shares are trading higher after the company reported preclinical data from an antiviral clinical drug candidate for Respiratory Syncytial Virus (RSV).
nanoViricides Inc. 紐約證券交易所代碼：NNVC）公佈了呼吸道合胞病毒（RSV）抗病毒臨床候選藥物的臨床前數據，此後，該公司股價走高。
The company reported on the strong effectiveness of its broad-spectrum antiviral clinical drug candidate NV-387 in an animal model of lethal lung infection with RSV.
該公司報告說，其廣譜抗病毒臨床候選藥物 NV-387 在呼吸道合胞病毒致命肺部感染的動物模型中具有很強的有效性。
NV-387 is the active ingredient of NV-CoV-2, the company's drug for COVID and possibly long COVID.
NV-387 是 nv-CoV-2 的活性成分，nv-CoV-2 是該公司治療冠狀病毒的藥物，可能還有很長的 COVID。
As previously reported, it is already in Phase 1a/1b human clinical trials for evaluating safety in healthy volunteers and of safety and preliminary efficacy in COVID patients.
正如先前報道的那樣，它已經進入1a/1b期人體臨床試驗，以評估健康志願者的安全性以及COVID患者的安全性和初步療效。
The company says that NV-387 can be advanced into Phase 2 studies against RSV once the current Phase 1 studies of NV-CoV-2 are completed. This will significantly speed up the development of the RSV drug, save costs, and improve return on investments.
該公司表示，一旦當前的nv-CoV-2第一階段研究完成，NV-387 就可以進入針對呼吸道合胞病毒的第二階段研究。這將顯著加快呼吸道合胞病毒藥物的開發，節省成本，提高投資回報率。
Two vaccines have recently been approved for RSV prophylaxis. GSK plc's (NYSE:GSK) Arexvy and Pfizer Inc's (NYSE:PFE) Abrysvo (for use in adults over 60 years of age and both reduced severity of RSV infection.
最近有兩種疫苗獲准用於呼吸道合胞病毒預防。 葛蘭素史克集團的 (紐約證券交易所代碼：GSK) Arexvy 和 輝瑞公司的 (NYSE: PFE) Abrysvo（用於60歲以上的成年人，兩者均可降低呼吸道合胞病毒感染的嚴重程度。
There are no vaccines currently approved for infants and children. There are no effective therapeutics for RSV to date.
目前尚無批准用於嬰兒和兒童的疫苗。迄今爲止，尚無有效的呼吸道合胞病毒治療方法。
Price Action: NNVC shares are up 27.70% at $1.80 on the last check Tuesday.
價格走勢： 週二最後一次支票顯示，NNVC股價上漲27.70％，至1.80美元。
譯文內容由第三人軟體翻譯。